

Second quarter 2024 results

Audiocast presentation 16 July 2024

Forward looking statements

This presentation contains forward-looking statements that provide our expectations or forecasts of future events such as new product developments and regulatory approvals and financial performance.

Camurus is providing the following cautionary statement. Such forward-looking statements are subject to risks, uncertainties and inaccurate assumptions. This may cause actual results to differ materially from expectations and it may cause any or all of our forward-looking statements here or in other publications to be wrong. Factors that may affect future results include currency exchange rate fluctuations, delay or failure of development projects, loss or expiry of patents, production problems, unexpected contract, patent, breaches or terminations, government-mandated or market-driven price decreases, introduction of competing products, Camurus' ability to successfully market products, exposure to product liability claims and other lawsuits, changes in reimbursement rules and governmental laws and interpretation thereof, and unexpected cost increases.

Camurus undertakes no obligation to update forward-looking statements.

Agenda

- Business highlights
- Financial performance
- Commercial development
- R&D pipeline update
- Key take-aways
- Q&A

Company participants

camurus

Fredrik Tiberg, PhD President & CEO, CSO

Jon Garay Alonso Chief Financial Officer

Richard Jameson Chief Commercial Officer

Business highlights

Strong profitability and operational execution



Positive financial development

- ✓ Revenues grew 46% YoY* to SEK 445 million
- ✓ Profit before tax was SEK 104 million
- ✓ Expect to finalize in the mid-to-high range of FY 2024 outlook
- ✓ Cash position at the end of June 2024 was SEK 2.6 billion



Commercial execution

- ✓ Strengthened global leadership in opioid dependence treatment
- ✓ Buvidal[®] net sales grew 31% YoY to SEK 400 million
- ✓ Brixadi[®] US royalties increased 73% QoQ to SEK 45 million
- ✓ US team onboarding for the launch of Oclaiz[™] planned around year end



Advancing R&D pipeline

- ✓ EU MAA for CAM2029 in acromegaly accepted for review by the EMA
- ✓ US NDA review for Oclaiz[™] with PDUFA date 21 October 2024
- ✓ Completion of the 52-week Phase 3 ACROINNOVA 2 study with positive final results
- ✓ Preparing for first clinical study of oncemonthly semaglutide

Financial performance


Strong revenue growth and result

MSEK 1000 958 835 800 674 +42% 600 447 445 400 +46% 227 200 0 Q2 H1 Q2 H1 Q2 H1 2022 2023 2024

Revenue

7

One-time revenue related to Brixadi US approvalRevenues excl. Brixadi US approval revenue



One-time revenue related to Brixadi US approval

Profit excl. Brixadi US approval revenue


Cash position SEK 2,567 million +292% vs O2 2023



Reported Q2 profit and loss

MSEK	Apr – Jun 2024	Change vs. 2023	CER Change vs. 2023	YTD Jan – Jun 2024	Change YTD vs. 2023	CER Change YTD vs. 2023
Total revenues excl. one-time milestones/license rev.	445	-34% <i>+46%</i>	-35% <i>+41%</i>	835	-13% <i>+42%</i>	-13% <i>+40%</i>
Gross margin excl. one-time milestones/license rev.	413	-285bps <i>+233bps</i>	-287bps <i>+258bps</i>	772	-148bps <i>+231bps</i>	-131bps <i>+265bps</i>
Marketing and distribution costs	-131	+39%	+39%	-224	+32%	+31%
Administrative expenses	-24	+97%	+96%	-40	+86%	+86%
Research and development costs	-174	+8%	+7%	-354	+36%	+36%
Other operating expenses/income	-2	_	_	6	+460%	_
Operating result excl. one-time milestones/license rev.	83	-78% +75 MSEK	-80% <i>+63 MSEK</i>	161	-64% <i>+81 MSEK</i>	-67% <i>+66 MSEK</i>
Profit before tax excl. one-time milestones/license rev.	104	-73% <i>+92 MSEK</i>	-74% <i>+80 MSEK</i>	201	-56% +113 MSEK	-58% <i>+99 MSEK</i>

Strong operational cash flow





FY 2024 guidance reiterated

expected to finalize in the mid to high end of the interval:

Revenue

SEK 1,740 – 1,860 million + 33 – 42% vs. 2023 excluding one-time revenues **Profit before taxes** SEK 330 – 450 million 131 – 215% vs. 2023 excluding one-time revenues

Commercial development

Buvidal – in-market growth continues

Sales growth across all markets


- Net sales Q2 2024: SEK 400 million; +31% YoY
 - Quarter-on-quarter growth invoiced sales 10% (6% at CER¹)
- Est. >53,000 patients in treatment with Buvidal end Q2 2024

Good growth seen across markets

- UK funding improved at clinic level
- Australia Buvidal >25% of all patients
- Germany improved penetration in community setting
- France growth in specialized centers and new funding
- Spain high penetration of buprenorphine segment

Market expansion

Four market authorization and several pricing and reimbursement applications under review



Quarterly sales reported and at CER¹

Solid Brixadi performance in the US


Continued strong growth of Brixadi

- 73% royalty growth QoQ
- Growth across all segments (Medicaid, commercial, federal and correction

Widening access to Brixadi for OUD in the US

- Payer support continued grow from an already high coverage
- Broad distribution network further expanded with additional specialty pharmacies and distributors

Peak market potential est. > USD 1 billion²



Brixadi royalty by quarter

Growing scientific evidence base

 New publication showing efficacy data for Buvidal/Brixadi in treating opioid dependence in individuals using fentanyl

Selected scientific conference participation in 2024:

	Q1/Q2 2024			Q3/Q4 2024		
Global		ASAM 4-7 Apr Dallas, US	CPDD III 15-19 Jun Montreal, CAN		ISAM C 5-8 Sep Istanbul, TR	
European		ALBATROS	EUROPAD 4 28-30 Jun Lisbon, PT		Lisbon Addict. 23-25 Oct Lisbon, PT	
National (selected)	CH Le Vinatier 11 Jan FR	WADD/SEPD = 17-20 Apr Mallorca, ES	Hospital Croix 17 May Lyon, FR	Suchmedizin – 4-6 Jul Munich, DE	Suchtsymp Oct Grundlsee, AT	DGPPN 29 Nov – 2 Dec Berlin, DE
	APP Terminal APP 14-17 Mar Cold Coast, AUS	Sigtunadagarna 18-19 Apr	Subst.Forum. — May Mondsee, AT	DANA To Aug 7-9 Aug AUS	RCPsych Addict Oct K London, UK	Gefängn.med 5-6 Dec Frankfurt,DE
	GRAAP 3 Apr Aix-en Prov, FR	AUS/NZ Addict. 29 Apr - 1 May Cold Coast, AUS	Federation Add 13-14 Jun Bordeaux, FR	SOCIDROGA. 26-28 Sep <i>Valencia, ES</i>	APSAD TO APSAD 30 Oct – 2 Nov Canberra, AUS	Addiktum H Dec <i>Helsinki, Fl</i>
	SESP (prisons) 23-25 May Vitoria-Gasteiz, ES	Le CLEF	WOWS June Brisbane, AUS	AFPBN 7-8 Oct Lyon, FR	Prison congr.	DGS-Kon. 1-3 Nov Leipzig, DE

Recent key publications

JAMA Network Open...

Original Investigation | Substance Use and Addiction Extended-Release Injection vs Sublingual Buprenorphine for Opioid Use Disorder With Fentanyl Use A Post Hoc Analysis of a Randomized Clinical Trial

Edward V. Nunes, MD: Sandra D. Comer, PhD: Michelle R. Lofwall, MD: Sharon L. Walsh, PhD; Stefan Peterson, PhD; Fredrik Tiberg, PhD; Peter Hjelmstrom, MD, PhD; Natalle R. Budilovsky-Kelley, PharmD

The uptake of long-acting depot buprenorphine for treating opioid dependence in Australia, 2019–2022: longitudinal sales data analysis

Nicholas Lintzeris^{1,2} 🐵 , Victoria Hayes^{2,3}, Adrian J Dunlop^{4,5} 😣

JAMA Network Open

Original Investigation | Substance Use and Addiction Extended-Release 7-Day Injectable Buprenorphine for Patients With Minimal to Mild Opioid Withdrawal

Gall D'Ondris. MD: Andrew A. Henring, MD: Janamard Perrone, MD: Kathryn Hawk, MD: Elitabeth A. Samuels, MD: Ethan Cowan, MD: Erik Anderson, MD: Ryan McComrack, MD, Kristen Hundley, FID, Patricia Owens, MS; Shara Martel, MPH; Mark Schactman, MHS; Michele R. Lofwall, MD; Sharon L. Walds, PHD; James Dzhara, PHD: David A. Fiellin, MD

<u>1 Nunes et al. JAMA Network Open. 2024;7(6)</u>
 <u>2 Lintzeris et al. MJA. 2024</u>
 <u>3 D'Onofrio et al. JAMA Network Open. 2024;7(7)</u>

R&D update

Positive topline Phase 3 results from ACROINNOVA 2 in patients with acromegaly

ACROINNOVA 2 trial design

- 52-week, open-label, long-term safety and extension trial

Patient population (N=135)

- New patients in trial; IGF-1<2xULN¹ (n=81)
- Roll-over CAM2029 patients; IGF-1≤1xULN² (n=36) from ACROINNOVA 1
- Roll-over placebo patients; IGF-1≤1xULN² (n=18) from ACROINNOVA 1


ACROINNOVA 2 (HS-19-647)

Primary endpoint:

- Long-term safety and tolerability

Secondary endpoints:


- Biochemical response (IGF-1, GH)
- Mean IGF-1 and GH over time
- Clinical signs and symptoms (AIS)
- Patient and treatment satisfaction (TSQM)
- Quality of life (AcroQoL)
- Self-Injection Assessment Questionnaire (SiAQ)
- Octreotide concentrations



IGF-1 – insulin-like growth factor-1; ULN – upper limit of normal; AIS – acromegaly index of severity; TSQM - treatment satisfaction questionnaire for medication; AcroQoL – acromegaly quality of life questionnaire; SiAQ – self injection assessment questionnaire; ¹At screening in ACROINNOVA 2; ²At screening in ACROINNOVA 1

Increased biochemical control during CAM2029 treatment in ACROINNOVA 2

Estimated difference in IGF-1 response rate at week 50/52 compared to SoC baseline



Patient populations

CAM2029 in ACROINNOVA 1: Roll-over patients from ACROINNOVA 1 controlled on SoC at baseline (IGF-1≤1×ULN)


New patients in ACROINNOVA 2: Patients with variable biochemical control on SoC at baseline (IGF-1<2xULN)

Model

Estimated within a linear probability model based on a binomial distribution and an identity link function with patient group, time and the interaction of patient group and time as fix factors, adjusted for previous treatment, and accounting for repeated subjects

Roll-over placebo patients regained biochemical control during CAM2029 treatment

Change from SoC and placebo baselines to week 50/52 of treatment with CAM2029



Patient population

Placebo in ACROINNOVA 1:


Roll-over patients on placebo in ACROINNOVA 1 controlled on SoC at screening (IGF-1≤1xULN)

Model

Estimated within a linear probability model based on a binomial distribution and an identity link function with patient group, time and the interaction of patient group and time as fix factors, adjusted for previous treatment, and accounting for repeated subjects

Acromegaly symptoms decreased during treatment with CAM2029


Continued symptom improvements from the SoC baseline



Acromegaly index of severity (AIS)

The AIS overall score was calculated as the sum of the scores for the 6 symptoms of headache, sweating, fatigue, joint pain, paresthesia and soft tissue swelling. The AIS overall score ranges from 0 (no symptoms) to 18 (severe symptoms)

camurus





Improvement in quality of life with CAM2029 treatment in ACROINNOVA 2

Quality of life scores (AcroQoL) improved for CAM2029 patients compared to SoC baseline




The Acromegaly Quality of Life (AcroQoL) questionnaire is a disease-specific scale that was used to assess quality of life in patients, scored from 0 to 100




Greater patient satisfaction with CAM2029 than with SoC in ACROINNOVA 2

Improvement in TSQM mean change from SoC baseline¹

Many patients rated experience of CAM2029 as "much better" than previous SoC



The Treatment Satisfaction Questionnaire for Medication (TSQM) is used to measure patient satisfaction with treatment, scored from 0 to 100



The **Patient Satisfaction Scale** rating overall treatment experience compared to previous treatment (SoC at baseline)

Confirmed long-term safety profile and tolerability

Summary of adverse events

	Overall
Category	(N=135) n (%)
AE	102 (75.6)
Related AE	74 (54.8)
Grade 1 AE	94 (69.6)
Grade 2 AE	47 (34.8)
Grade 3 AE	17 (12.6)
Related grade 3 AE	0
SAE	15 (11.1)
Related SAE	1 (0.7) ¹
Fatal SAE	0
AE leading to treatment discontinuation	2 (1.5)
AE leading to dose reduction	1 (0.7) ²

CAM2029 was generally well tolerated with a consistent safety-profile to SoC

- Most common AEs were mild to moderate, transient injection site reactions and gastrointestinal events
- No severe AEs related to CAM2029
- One patient had a treatment-related SAE, which resolved, and the patient continued treatment in the trial
- Two patients discontinued treatment due to an AE; a mild depression and a mild injection site reaction
- No new safety signals in AEs, ECGs, or labs

Overall conclusions from ACROINNOVA 2

- CAM2029 was well tolerated, with no new or unexpected safety signals
- Increased or maintained response (IGF-1≤1) over 52 weeks of CAM2029 treatment
 - Increased response rate from SoC baseline in new recruited patients (IGF-1<2 at screening)
 - Maintained response from SOC baseline in roll-over patients (IGF-1≤1 at screening)
 - Regained response in prior placebo treated roll-over patients (IGF-1≤1 at screening)
- Symptom improved from SoC baseline during 52 weeks of treatment with CAM2029
- Patient-reported treatment satisfaction and quality of life improved from SoC baseline to week 52
- CAM2029, if approved, has the potential to become a new treatment alternative and address key unmet medical needs for patients with acromegaly

CAM2029 progressing towards market with upcoming key milestones 2024/25

AcroInnova[™]

Pivotal randomized placebo controlled and long-term safety trials in acromegaly

- ✓ Positive ACROINNOVA 1 results
- ✓ NDA acceptance for review
- ✓ MAA submission to EMA
- ✓ Positive ACROINNOVA 2 complete core phase results
- NDA PDUFA date 21 Oct 2024
- □ US launch readiness for Oclaiz[™] around year end 2024
- MAA approval by EMA est. mid-2025

SORENTO

Subcutaneous Octreotide Randomized Efficacy in Neuroendocrine TumOrs

- ✓ SORENTO Phase 3 start Q4 2021
- ✓ SORENTO fully enrolled Q4 2023
- □ Topline result est. H1 2025
- NDA/MAA submission est. H2 2025



Polycystic liver Safety and efficacy TriAl with subcutaneous Octreotide

- ✓ POSITANO Phase 2/3
 Q2 2022
- ✓ POSITANO fully enrolled Q1 2024
- **D** Topline result H1 2025

High medical affairs activity in preparation for launch of Oclaiz^{\ensuremath{\mathsf{TM}}}

Participation at international meetings

Multiple presentations (oral and posters) of ACROINNOVA data at leading conferences:

- American Association of Clinical Endocrinology meeting, AACE 2024, in New Orleans³
- European Congress of Endocrinology meeting, ECE 2024, in Stockholm¹
 - Satellite symposium on new and upcoming treatments for acromegaly
- Endocrine Society meeting, ENDO 2024, in Boston²

Key scientific conferences for CAM2029 in 2024



On track to deliver our 2024 goals

- Solid growth for Buvidal in Europe and Australia
- Continued strong launch momentum for Brixadi in the US
- US NDA and EU MAA review processes for CAM2029 in acromegaly on track US PDUFA date 21 October 2024
- Significant progress in late and early-stage pipeline programs
- Revenue and profitability full year 2024 guidance reiterated
 expected in the mid-to-high range of the interval







Shareholders and analyst coverage

Shareholders as of 28 June 2024	Number of shares	% of capital	% of votes
Sandberg Development AB	20,530,692	35.0	35.2
Fjärde AP-fonden	2,610,766	4.5	4.5
JP Morgan Chase Bank	2,107,664	3.6	3.6
Swedbank Robur Fonder	1,955,941	3.3	3.4
Avanza Pension	1,724,043	2.9	3.0
Fredrik Tiberg, CEO	1,615,000	2.8	2.8
State Street Bank and Trust	1,537,487	2.6	2.6
Handelsbankens fonder	1,509,212	2.6	2.6
The Bank of New York Mellon SA/NV	874,035	1.5	1.5
Norges bank	695,363	1.2	1.2
Afa Försäkring	692,293	1.2	1.2
The Bank of New York Mellon	688,801	1.2	1.2
CS Client Omnibus	611,617	1.0	1.1
JP Morgan SE	577,106	1.0	1.0
SEB Investment Management	560,565	1.0	1.0
Other shareholders	20,346,333	34.7	34.4
in total	58,636,918	100.0	100.0

Analysts

Carnegie Erik Hultgård

DNB Patrik Ling

Handelsbanken Mattias Häggblom

Jefferies Brian Balchin

Nordea Viktor Sundberg

Pareto Dan Akschuti

Bryan Garnier Oscar Haffen Lamm

SEB Christopher Uhde

Experienced and committed management team



Fredrik Tiberg, PhD President & CEO, CSO In Company since 2002 Holdings: 1,615,000 shares, 102,000 employee options and 4.000 PSP units



Richard Jameson Chief Commercial Officer In Company since: 2016 Holdings: 29,193 shares, 24,000 employee options and 2,300 PSP units

Markus Johnsson Senior VP R&D In Company since: 2003-2017, 2019-Holdings: 21,000 shares, 9,500 employee options and 1,500 PSP units



Torsten Malmström, PhD Chief Technical Officer In Company since 2013 Holdings: 45,363 shares, 16,000 employee options and 1,500 PSP units

Alberto M. Pedroncelli Chief Medical Officer In Company since 2023 Holdings: 1,000 shares, 20,000 employee options and 1,500 PSP units

Agneta Svedberg VP Clinical Dev. In Company since: 2015 Holdings: 22.987 shares, 16.000 employee options and 1,500 PSP units

Education: M.Sc. in Chemistry, PhD in Inorganic Chemistry, Lund University

Previous experience: More than 20 years of experience from pharmaceutical R&D including Director Pharmaceutical Development at Zealand Pharma, Director of Development at Polypeptide, Team Manager at AstraZeneca.

Education: M.Sc. in Chem. Eng., Lund Institute of Technology,

PhD and Assoc. Prof. Physical Chemistry, Lund University.

leadership experience from the pharmaceutical industry.

Prof Physical Chemistry, Lund University; Visiting Prof at

Previous experience: General Manager, UK & Nordics for

Reckitt Benckiser (2010 – 2013) and Area Director Europe.

Previous experience: More than 20 years of experience from

pharmaceutical development and project management

Education: B.Sc. in Applied Biological Sciences from

Middle East and Africa for Indivior (2013 - 2016).

Education: Ph.D. in physical chemistry and M.Sc. in

University West of England

chemistry from Uppsala University.

Oxford University; Section Head, Inst. for Surface Chemistry.

Previous experience: More than 20 years executive

Education: MD University of Milan. Ph. D. endocrinology post-graduate school University of London Previous experience: Head of Clinical Development and Medical Affairs Recordati, Senior Leadership positions Novartis, clinician and research fellow Dept. Endocrinology, University Hospital Bergamo, Italy

Education: M.Sc. In Radiophysics and B.Sc. In Medicine from Lund University, Executive MBA from Executive Foundation Lund

Previous experience: More than 25 years of experience in drug development, incl. as COO at Zealand Pharma, CEO of Cantargia, Senior VP Clinical Development at Genmab.



n 6.

Fredrik Joabsson, PhD Chief Business Dev. Officer In Company since 2001 Holdings: 50,170 shares, 16,000 employee options and 1,500 PSP units

Maria Lundovist Head of Global HR In Company since 2021 Holdings: 16,000 employee options and 1,500 PSP units



VP Regulatory Affairs In Company since: 2017 Holdings: 2,004 shares, 16,000 employee options and 1,500 PSP units

Behshad Sheldon

President Camurus Inc. In Company since 2024 Holdings: 1.000 shares, 2.000 employee options and 1,500 PSP units

Education: Bachelor in Business Administration by Universidad Comercial de Deusto. Executive MBA by IESE Business School.

Previous experience: More than 20 years experience from Finance within pharmaceutical and medtech companies, incl. Baxter, Gambro, Convatec, Bristol Myers Squibb.

Education: M.Sc. in Chemistry, PhD in Physical Chemistry, Lund University

Previous experience: More than 20 years of experience in pharmaceutical R&D, business development, alliance management and investor relations.

Education: B.Sc: in Business and Economics, Uppsala University.

Previous experience: More than 20 years of experience of leadership roles within Human Resources, including HR Director Nordics at Teva Pharmaceuticals and HR positions at Tetra Pak, Vestas and AstraZeneca.

Education: Bachelor of Pharmacy, Uppsala University and Business Economics, Lund University Previous experience: More than 25 years of experience within regulatory affairs, including European RA Director/Global RA Lead at AstraZeneca and Global RA Lead at LEO Pharma.

Education: B.Sc. in Neuroscience from University of Rochester **Previous experience:** More than 25 years of experience from the international pharma industry, including President & CEO of Braeburn Pharmaceuticals and senior positions within Smithkline Beecham, Bristol-Myers Squibb and Otsuka Pharmaceuticals.

Broad and diversified product portfolio and pipeline

